No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Teva Subsidiary to Launch Unbranded Ustekinumab Biosimilar in US via MedImpact
On 18 August 2025, MedImpact Holdings Inc. announced that, from 1 January 2026, Teva subsidiary Anda’s unbranded ustekinumab-aekn (biosimilar to J&J/Janssen’s Stelara®) will be available for direct purchase from MedImpact’s preferred partner, Birdi, Inc.